Skip to main content

Day: April 9, 2025

PodcastOne (NASDAQ: PODC) Video Views Surge 218% Year-Over-Year Across Platforms Including YouTube, Rumble, Substack, Spotify, TikTok and Apple+

Company to Support Video Distribution for Entire Roster of Produced Programming by the End of 2025 PodcastOne Ranked as 9th Largest U.S. Podcast Publisher for March 2025 LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) — PodcastOne (NASDAQ: PODC), a leading publisher and podcast sales network, announced today a 218% year-over-year increase in video views, reflecting its acceleration and investment in diversifying its content offerings and expanding its audience reach. PodcastOne’s shows are distributed across leading video streaming services such as YouTube, Rumble, Substack, Spotify, TikTok and Apple+. With the podcasting landscape evolving, PodcastOne has strategically broadened its video production capabilities and distribution for its podcast offerings, enabling listeners the option to engage with content in a more dynamic and...

Continue reading

Silicon Motion Announces First Quarter 2025 Earnings Conference Call

TAIPEI, Taiwan and MILPITAS, Calif., April 09, 2025 (GLOBE NEWSWIRE) — Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”), a global leader in NAND flash controllers for solid state storage devices, plans to release its first quarter 2025 financial results after the market closes on April 29, 2025 and will host a conference call on April 30 at 8:00 a.m. Eastern Time. Participants must pre-register using the link below to participate in the live call.   CONFERENCE CALL DETAILS: Participants must register in advance to join the conference call using the link provided below. Conference access information (including dial-in information and a unique access PIN) will be provided in the email received upon registration. Participant Online Registration:https://register-conf.media-server.com/register/BI5c69a4c2d96041b59a2bf8a51cec1881 This...

Continue reading

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026. This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 (“CLDN6”) x CD3 TCE bispecific...

Continue reading

South Bow Responds to Pipeline Incident at Milepost 171

CALGARY, Alberta, April 09, 2025 (GLOBE NEWSWIRE) — South Bow Corp. (TSX & NYSE: SOBO) (South Bow or the Company) has shut down the Keystone Pipeline (Keystone) and is actively responding to an oil release at Milepost 171 (MP-171) of Keystone, near Fort Ransom, North Dakota. Aligned with incident protocols, South Bow initiated a shutdown and response at approximately 7:42 a.m. CT on April 8, 2025, after control centre leak detection systems detected a pressure drop in the system; the system was shut down at 7:44 a.m. CT on April 8, 2025. The affected segment has been isolated, and the release has been contained. The estimated release volume is approximately 3,500 barrels. Onsite staff, the surrounding community, and mitigating risk to the environment are South Bow’s primary concern. Upon activating emergency response...

Continue reading

Watsco Schedules First Quarter Conference Call On Wednesday, April 23, 2025

MIAMI, April 09, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today that it has scheduled a conference call to discuss its 2025 first quarter results on Wednesday, April 23, 2025 at 10:00 a.m. (EDT). Prepared remarks regarding the results will be followed by a question-and-answer session with the senior management team. The conference call will be web-cast by CCBN’s StreetEvents and can be found under the link highlighted on our website at www.watsco.com. The earnings results will be released before the market opens on February 18, 2025. A replay of the conference call will be available on our website. Investors and analysts are encouraged to pre-register for the conference call by using the link below. Participants who pre-register will be given a unique PIN to gain immediate access to the call. Pre-registration...

Continue reading

Amerigo Reports Q1-2025 Operational Results

Q1-2025 copper production of 13.2 million pounds Results in line with 2025 guidance of 62.9 million pounds of copper Scheduled annual plant maintenance shutdown completed in Q1-2025 Capital return to shareholders of $4.6 million in Q1-2025 VANCOUVER, British Columbia, April 09, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce operational results for the quarter ended March 31, 2025 (“Q1-2025”) from Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile. Dollar amounts in this news release are in U.S. dollars (“USD”) unless indicated otherwise. In Q1-2025, MVC produced 13.2 million pounds (“M lbs”) of copper and 0.24 M lbs of molybdenum. During the quarter, MVC’s plant availability was 97.6%, and there were no lost-time...

Continue reading

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA Latest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular riskMONTREAL, April 09, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the first quarter 2025, ended February 28, 2025. All figures are in U.S. dollars unless otherwise stated. First-Quarter 2025 Revenues(in thousands of U.S. dollars)  Three Months Ended Change  February 28,2025   February 29,2024    EGRIFTA...

Continue reading

Verde Agritech Limited and Nautica Holdings Limited announce strategic transaction for high-grade magnetic rare earths exploration assets

SINGAPORE, April 09, 2025 (GLOBE NEWSWIRE) — Verde Agritech Ltd (TSX: “NPK”) (OTCQX: “VNPKF”) (“Verde” or the “Company”) and Nautica Holdings Limited (ACN 647 075 401), an Australian unlisted public company with AUD $1 million in cash available for investment, are pleased to jointly announce the execution of a Share Sale Agreement (“SSA”). Under the SSA, Nautica will acquire high-grade magnetic rare earths exploration assets located in Brazil (“Exploration Assets“) from Verde’s subsidiary, Oby Rare Earths Pty Ltd (“Oby”). This strategic transaction enables Verde to realize value for its shareholders and positions Nautica as a significant player in the rare earths sector, capitalizing on increasing global demand for critical minerals. The AUD $1 million available in Nautica will be specifically allocated...

Continue reading

Bitdeer Announces March 2025 Production and Operations Update

— Completed mass production of SEALMINER A1s and 2.8 EH/s energized— Regulatory approval for Tydal, Norway site finalized— Retained Northland Capital Markets (“Northland”) to act as financial advisor for its HPC/AI data center development strategy SINGAPORE, April 09, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited mining and operations updates for March 2025. Operational UpdateSelf-mined Bitcoin: 114 Bitcoins. Mining Rig Manufacturing and R&D:SEALMINER A1:Completed mass production of approximately 3.8 EH/s of mining rigs. 2.8 EH/s are energized, 0.6 EH/s have been delivered for installation, 0.3 EH/s are in-transit to the Company’s datacenters,...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 08 04 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.